Literature DB >> 15741255

Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation.

Ludmila Matyakhina1, Reneé J Freedman, Isabelle Bourdeau, Ming-Hui Wei, Sotirios G Stergiopoulos, Aaron Chidakel, McClellan Walther, Mones Abu-Asab, Maria Tsokos, Meg Keil, Jorge Toro, W Marston Linehan, Constantine A Stratakis.   

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder caused by mutations in the fumarate hydratase (FH) gene on chromosome 1q42.3-43. Massive macronodular adrenocortical disease (MMAD) is a heterogeneous condition associated with Cushing syndrome (CS) and bilateral hyperplasia of the adrenal glands. In MMAD, cortisol secretion is often mediated by ectopic, adrenocortical expression of receptors for a variety of substances; however, to date, no consistent genetic defects have been identified. In a patient with HLRCC caused by a germline-inactivating FH mutation, we diagnosed atypical (subclinical) CS due to bilateral, ACTH-independent adrenocortical hyperplasia. A clinical protocol for the detection of ectopic expression of various hormone receptors was employed. Histology was consistent with MMAD. The tumor tissue harbored the germline FH mutation and demonstrated allelic losses of the 1q42.3-43 FH locus. We then searched the National Institutes of Health (NIH) databases of patients with MMAD or HLRCC and found at least three other cases with MMAD that had a history of tumors that could be part of HLRCC; among patients with HLRCC, there were several with some adrenal nodularity noted on computed tomography but none with imaging findings consistent with MMAD. From two of the three MMAD patients, adrenocortical tumor DNA was available and sequenced for coding FH mutations; there were none. We conclude that in a patient with HLRCC, adrenal hyperplasia and CS were due to MMAD. The latter was likely due to the FH germline mutation because in tumor cells, only the mutant allele was retained. However, other patients with MMAD and HLRCC, or HLRCC patients with adrenal imaging findings consistent with MMAD, or MMAD patients with somatic FH mutations were not found among the NIH series. Although a fortuitous association cannot be excluded, HLRCC may be added to the short list of monogenic disorders that have been reported to be associated with the development of adrenal tumors; FH may be considered a candidate gene for MMAD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741255     DOI: 10.1210/jc.2004-2377

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

2.  MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis.

Authors:  Eirini I Bimpaki; Dimitrios Iliopoulos; Andreas Moraitis; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2009-10-22       Impact factor: 3.478

Review 3.  Genetics of Adrenocortical Development and Tumors.

Authors:  Maya Lodish
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-22       Impact factor: 4.741

Review 4.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

5.  Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.

Authors:  Fabio R Faucz; Mihail Zilbermint; Maya B Lodish; Eva Szarek; Giampaolo Trivellin; Ninet Sinaii; Annabel Berthon; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Jerome Bertherat; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2014-03-06       Impact factor: 5.958

6.  ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome.

Authors:  Guillaume Assié; Rossella Libé; Stéphanie Espiard; Marthe Rizk-Rabin; Anne Guimier; Windy Luscap; Olivia Barreau; Lucile Lefèvre; Mathilde Sibony; Laurence Guignat; Stéphanie Rodriguez; Karine Perlemoine; Fernande René-Corail; Franck Letourneur; Bilal Trabulsi; Alix Poussier; Nathalie Chabbert-Buffet; Françoise Borson-Chazot; Lionel Groussin; Xavier Bertagna; Constantine A Stratakis; Bruno Ragazzon; Jérôme Bertherat
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

Review 7.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

8.  Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family.

Authors:  Carolina Arenas Valencia; Martha Lucia Rodríguez López; Andrea Yimena Cardona Barreto; Edgar Garavito Rodríguez; Clara Eugenia Arteaga Díaz
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

9.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

Review 10.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.